1. Home
  2. ALLK vs SOS Comparison

ALLK vs SOS Comparison

Compare ALLK & SOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLK
  • SOS
  • Stock Information
  • Founded
  • ALLK 2012
  • SOS 2004
  • Country
  • ALLK United States
  • SOS China
  • Employees
  • ALLK N/A
  • SOS N/A
  • Industry
  • ALLK Biotechnology: Pharmaceutical Preparations
  • SOS Finance: Consumer Services
  • Sector
  • ALLK Health Care
  • SOS Finance
  • Exchange
  • ALLK Nasdaq
  • SOS Nasdaq
  • Market Cap
  • ALLK 23.0M
  • SOS 21.7M
  • IPO Year
  • ALLK 2018
  • SOS 2017
  • Fundamental
  • Price
  • ALLK $0.32
  • SOS $4.56
  • Analyst Decision
  • ALLK Hold
  • SOS
  • Analyst Count
  • ALLK 3
  • SOS 0
  • Target Price
  • ALLK $2.00
  • SOS N/A
  • AVG Volume (30 Days)
  • ALLK 1.8M
  • SOS 9.4K
  • Earning Date
  • ALLK 03-12-2025
  • SOS 01-01-0001
  • Dividend Yield
  • ALLK N/A
  • SOS N/A
  • EPS Growth
  • ALLK N/A
  • SOS N/A
  • EPS
  • ALLK N/A
  • SOS N/A
  • Revenue
  • ALLK N/A
  • SOS $111,124,000.00
  • Revenue This Year
  • ALLK N/A
  • SOS N/A
  • Revenue Next Year
  • ALLK N/A
  • SOS N/A
  • P/E Ratio
  • ALLK N/A
  • SOS N/A
  • Revenue Growth
  • ALLK N/A
  • SOS N/A
  • 52 Week Low
  • ALLK $0.22
  • SOS $4.30
  • 52 Week High
  • ALLK $1.56
  • SOS $21.30
  • Technical
  • Relative Strength Index (RSI)
  • ALLK 59.90
  • SOS 36.60
  • Support Level
  • ALLK $0.24
  • SOS $4.30
  • Resistance Level
  • ALLK $0.27
  • SOS $5.00
  • Average True Range (ATR)
  • ALLK 0.01
  • SOS 0.27
  • MACD
  • ALLK 0.01
  • SOS 0.03
  • Stochastic Oscillator
  • ALLK 96.94
  • SOS 28.81

About ALLK Allakos Inc.

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of big data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other service. The company has has three reporting segments: Commodity trading, Cryptocurrency mining and Others. Key revenue is generated from Commodity trading.

Share on Social Networks: